This clinical trial is focused on studying the effectiveness, safety, and tolerability of a medication called Atogepant for the preventive treatment of Menstrual Migraine. Menstrual Migraine is a type of headache that occurs in connection with a woman’s menstrual cycle. The study aims to see how well Atogepant works in preventing these migraines compared to a placebo, which is a substance with no active medication.

Participants in the study will be randomly assigned to receive either Atogepant or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the main part of the study. This helps ensure that the results are not biased. The study will also include an “open-label extension,” where all participants may receive Atogepant after the initial phase, allowing researchers to gather more information about the medication’s long-term effects.

The main goal of the study is to evaluate how Atogepant, taken for seven consecutive days, affects the number of migraine days during the perimenstrual period, which is the time around the start of menstruation. The study will look at changes in the number of migraine days over three menstrual cycles. Participants will be monitored for any side effects and how well they tolerate the medication. The study is expected to continue until 2027, providing valuable insights into the potential benefits of Atogepant for those suffering from Menstrual Migraine.